.png){kind=icon}
.png){kind=icon}
Return
Dawn of a new era in olfactory regeneration: Pediatric stem cell therapy enters the era of long-term validation
.png){kind=icon}
PRE
AI
G
J
Y
M
DOI：10.4252/wjsc.v18.i1.114751.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
A recently published prospective study marks a breakthrough for congenital olfactory disorders in children. The study provides the first long-term, three-year follow-up data, robustly demonstrating the durable efficacy and safety of autologous nasal epithelial stem cell transplantation. This work reveals immense therapeutic potential for a condition traditionally considered untreatable. However, this milestone achievement also presents new challenges. To translate this pioneering therapy from a single-center success to a global standard, multicenter, controlled clinical trials must be initiated immediately. Only through rigorous validation can we ensure its widespread adoption and ultimately bring hope to millions of children worldwide.
Keywords:
Congenital olfactory disorders
Nasal epithelial stem cells
Pediatric anosmia
Stem cell therapy
Clinical translation
Regenerative medicine
Journal
IF:
3.6
Papers:
827
Citations:
2.8K
Organization
Cited Papers